Get the app
US › Healthcare

GRAIL, LLC (GRAL)

US · Healthcare · Diagnostics & Research

$117.81-13.03%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$44.7M
Revenue YoY
+25.7%
Net profit
$-110.2M
EPS
$-2.56
EPS estimate
$-2.91
Net margin
-246.7%

EPS came in at -2.56 against a street estimate of -2.91 — a beat of 12.0%.

Key statistics

Market cap
$6.05B
Forward P/E
0.0
P/B
1.91
Book value
$56.93
EPS (TTM)
$-9.66
52-week high
$166.47
52-week low
$41.50
50-day MA
$96.23
200-day MA
$75.65
Beta
2.84

Analyst view

Analysts rate GRAIL, LLC a buy (5 buy, 6 hold, 0 sell out of 11) with an average price target of $131.30.

From the latest earnings call · 2026-08-05

CONFIDENT GRAIL posted 26% revenue growth to $44.7M on 35% volume growth. Galleri detected 6.5× more cancers vs. standard care. FDA AdCom expected fall 2026; approval anticipated early 2027. Samsung $110M investment backs Asian expansion. Q2 2026 U.S. driving volume; NHS organizational changes creating near-term uncertainty but clinician enthusiasm remains high. Samsung partnership to drive Asia expansion starting South Korea. Analysts pressed on AdCom timing and specificity of FDA communication; management reaffirmed expectation but no new public details. Pricing pressure and competitive noise addressed via rigorous data differentiation and sales follow-up. Medicare NCD timing left speculative. 2026-08-05…

Full summary in the app.

Shareholding

Insiders
4.92%
Institutions
86.30%

Largest institutional holders

FundStake
Farallon Capital Management, L.L.C.9.32%
Baker Bros Advisors LP9.02%
BlackRock Inc8.01%
Fort Hoosac Management, LLC6.95%
State Street Corp5.34%
PRIMECAP Management Company4.88%
Sessa Capital, L.P4.56%
Deep Track Capital, LP4.11%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
GRAIL, INC. - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Securities Position: $55.6 million cash + $806.0 mill
2026-08-06
Results announced · Q3 2026
GRAIL Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $44.7 million, up 26% year-over-year • Q2 2026 Galleri Screening R
2026-08-05
Shareholder vote results · Q2 2026
GRAIL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 18, 2026 • 35,076,394 shares represented (81.7% of 42,916,593 total share
2026-06-22
Board / officer change · Q2 2026
GRAIL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Dr. Joshua Ofman appointed as Chief Executive Officer effective June 1, 2026 • Annual base salary
2026-06-01
Quarterly report · Q1 2026
GRAIL, Inc. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $69.3 million in cash and cash equivalents; $753.8 million in short-term market
2026-05-07
Results announced · Q2 2026
GRAIL Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $40.8 million, up 28% year-over-year • Galleri screening revenue: $39.8 mi
2026-05-05
Proxy statement · Q2 2026
GRAIL, INC. — 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect Steven Mizell and Sarah Krevans as Class II Dire
2026-04-28
Annual report FY2025
GRAIL, INC. - FORM 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Company: GRAIL, Inc. (Ticker: GRAL, Nasdaq) • Fiscal Year Ended: Decemb
2026-03-12

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GRAIL, LLC — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-10-19.